Cargando…

Born to survive: how cancer cells resist CAR T cell therapy

Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be due to CAR T cells dysfunction, a hostile tumor microenvironment, or resistant cancer cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lemoine, Jean, Ruella, Marco, Houot, Roch
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609883/ https://www.ncbi.nlm.nih.gov/pubmed/34809678 http://dx.doi.org/10.1186/s13045-021-01209-9

Ejemplares similares

CAR-T cells and BiTEs in solid tumors: challenges and perspectives
por: Edeline, Julien, et al.
Publicado: (2021)

Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
por: Drillet, Gaëlle, et al.
Publicado: (2022)

Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy
por: Gabrielli, Giulia, et al.
Publicado: (2023)

T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
por: Messéant, Ondine, et al.
Publicado: (2021)

Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy
por: Nair, Ranjit, et al.
Publicado: (2020)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

How CAR T Cells Breathe
por: Forcados, Christopher, et al.
Publicado: (2022)

How Can We Engineer CAR T Cells to Overcome Resistance?
por: Glover, Maya, et al.
Publicado: (2021)

How I treat adverse effects of CAR-T cell therapy
por: Yáñez, Lucrecia, et al.
Publicado: (2020)

The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
por: Cerrano, Marco, et al.
Publicado: (2020)

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
por: Lemoine, Jean, et al.
Publicado: (2023)

Adoptive T-cell therapy for Hodgkin lymphoma
por: Ho, Carrie, et al.
Publicado: (2021)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
por: Kim, Gloria B., et al.
Publicado: (2019)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

CAR-T Cell Therapy: From the Shop to Cancer Therapy
por: Uscanga-Palomeque, Ashanti Concepción, et al.
Publicado: (2023)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
por: Louie, Raymond Hall Yip, et al.
Publicado: (2023)

Donor T cells for CAR T cell therapy
por: Tang, Tiffany C. Y., et al.
Publicado: (2022)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
por: Cai, Qing, et al.
Publicado: (2020)

CAR‐T therapy: Prospects in targeting cancer stem cells
por: Cui, Xiaoyue, et al.
Publicado: (2021)

CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer
por: Bębnowska, Dominika, et al.
Publicado: (2020)

CAR‐T cell therapy for lung cancer: Potential and perspective
por: Chen, Long, et al.
Publicado: (2022)

The current landscape of single-cell transcriptomics for cancer immunotherapy
por: Guruprasad, Puneeth, et al.
Publicado: (2020)

CAR T Cell Therapy: A Versatile Living Drug
por: De Marco, Rodrigo C., et al.
Publicado: (2023)

Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
por: Song, Moo-Kon, et al.
Publicado: (2019)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

Global Manufacturing of CAR T Cell Therapy
por: Levine, Bruce L., et al.
Publicado: (2016)

CAR-T Cell Therapy and the Gut Microbiota
por: Asokan, Sahana, et al.
Publicado: (2023)

CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
por: Zhang, Xi-Wen, et al.
Publicado: (2023)

Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
por: Ma, Hong Yun, et al.
Publicado: (2023)

CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy
por: Shademan, Behrouz, et al.
Publicado: (2022)

How I treat cytopenias after CAR T-cell therapy
por: Jain, Tania, et al.
Publicado: (2023)

CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead
por: Zhang, Qingyang, et al.
Publicado: (2020)

CAR T-cell therapy and critical care: A survival guide for medical emergency teams
por: Messmer, Anna S., et al.
Publicado: (2021)

CAR-T cell therapy in ovarian cancer: from the bench to the bedside
por: Zhu, Xinxin, et al.
Publicado: (2017)

Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
por: Hosseinkhani, Negar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_49p960odu4u0oor47c3au9noib